Roche has received European Commission approval for its Tecentriq drug in combination with Avastin and chemotherapy as an initial treatment for people with a specific type of lung cancer, the Swiss pharma company is quoted in Reuters Health as saying.
The combination has been approved as a first-line treatment for people with metastatic non-squamous non-small cell lung cancer (NSCLC).
NSCLC is the most common type of lung cancer, accounting for about 85% of all cases, Roche said.
[link url="https://www.reuters.com/article/us-roche-lungcancer/roche-gets-european-approval-for-tecentriq-combo-vs-lung-cancer-idUSKCN1QP0JJ"]Reuters Health report[/link]